Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from IP Group plc ( (GB:IPO) ).
IP Group portfolio company Enterprise Therapeutics has reported positive Phase 2 trial results for ETD001, its lead inhaled therapy targeting the 10% of cystic fibrosis patients with the greatest unmet need. The 28-day study met its primary efficacy endpoint, showing a clinically meaningful improvement in lung function versus placebo, with an overall well-tolerated safety profile consistent with expectations for this patient group.
Enterprise plans to move ETD001 into longer-duration Phase 2b studies, including in combination with existing CFTR modulator therapies and in other muco-obstructive lung diseases where significant unmet need remains. IP Group’s chief executive described the data as a key clinical milestone that validates Enterprise’s differentiated approach to cystic fibrosis and underscores IP Group’s strategy of giving investors exposure to high-potential deep science ventures.
The most recent analyst rating on (GB:IPO) stock is a Buy with a £110.00 price target. To see the full list of analyst forecasts on IP Group plc stock, see the GB:IPO Stock Forecast page.
Spark’s Take on IPO Stock
According to Spark, TipRanks’ AI Analyst, IPO is a Neutral.
The score is held back primarily by volatile operating performance and weak, inconsistent cash generation despite a 2025 profitability rebound. This is partially offset by a resilient balance sheet, constructive price momentum above key moving averages, and a relatively low P/E valuation.
To see Spark’s full report on IPO stock, click here.
More about IP Group plc
IP Group plc is a UK-based early-stage science and technology investor listed on the London Stock Exchange. Focusing on healthtech, deeptech and cleantech, it backs innovations emerging from leading universities and research institutions, including via Parkwalk, the UK’s largest growth EIS fund manager, and has supported companies such as Oxford Nanopore Technologies and Hinge Health.
Average Trading Volume: 3,751,561
Technical Sentiment Signal: Buy
Current Market Cap: £574.2M
For an in-depth examination of IPO stock, go to TipRanks’ Overview page.